Valuation: VISEN Pharmaceuticals

Market Cap	2.49B 2.88B 367M 321M 295M 275M 522M 34.97B 530M 3.54B 1.38B 17.19B 1.38B 1.35B 59.24B	P/E 2026 *	-24.3x	P/E 2027 *	-40.8x
Enterprise Value	2.23B 2.58B 329M 287M 264M 246M 467M 31.29B 474M 3.17B 1.23B 15.38B 1.23B 1.21B 53B	EV / Sales 2026 *	32.9x	EV / Sales 2027 *	5.57x
Free-Float	19.09%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : VISEN Pharmaceuticals

06-26	VISEN Pharmaceuticals Announces Board Appointments, Effective June 26, 2026	CI
05-17	VISEN Pharmaceuticals commences an Equity Buyback Plan for 11,392,686 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2025.	CI
04-24	WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site	CI
03-20	Certain Shares of VISEN Pharmaceuticals are subject to a Lock-Up Agreement Ending on 20-MAR-2026.	CI
03-12	Visen Pharmaceuticals posts loss for year of RMB253.4 million	RE
03-11	VISEN Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-26	Visen Pharmaceuticals says NMPA approves lonapegsomatropin (Skytrofa) for injection	RE
01-26	VISEN Pharmaceuticals' Growth Hormone Replacement Therapy Approved in China	MT
01-26	National Medical Products Administration Approves Biologics License Application for Lonapegsomatropin for Injection	CI
13/10/25	VISEN Pharmaceuticals Appoints Lu Ying as the Chief Financial Officer, Effective from October 13, 2025	CI
13/10/25	VISEN Pharmaceuticals Names CFO	MT
13/10/25	Visen Pharmaceuticals appoints Lu Ying as CFO	RE
22/09/25	VISEN Pharmaceuticals(SEHK:2561) added to S&P Global BMI Index	CI

More news

Managers and Directors: VISEN Pharmaceuticals

Manager	Title	Age	Since
An Bang Lu CEO	Chief Executive Officer	60	06/11/2018
Ying Lu DFI	Director of Finance/CFO	42	12/10/2025
Jun Yang CTO	Chief Tech/Sci/R&D Officer	54	31/03/2020

Director	Title	Age	Since
An Bang Lu BRD	Director/Board Member	60	06/11/2018
Yi Bo Cao BRD	Director/Board Member	44	07/01/2021
Zheng Bin Yao BRD	Director/Board Member	60	31/03/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VISEN PHARMACEUTICALS	+5.68%	+33.10%	-42.69%	-	367M
LONZA GROUP AG	+1.70%	+7.41%	+3.12%	+8.46%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+11.89%	+38.86%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+13.67%	+19.09%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+99.12%	13.52B
Average	+2.52%	+8.55%	+66.30%	+120.30%	24.6B
Weighted average by Cap.	+2.07%	+6.57%	+90.53%	+137.74%

See all sector performances

Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	HK$26.42	+5.68%	44,000
02/07/26	HK$25.00	+25.13%	168,900
30/06/26	HK$19.98	-0.10%	5,200
29/06/26	HK$20.00	+0.76%	8,500
26/06/26	HK$19.85	+0.20%	5,700

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.86CNY

Average target price

44.50CNY

Spread / Average Target

+94.61%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. Other stock markets 09:08:15 03/07/2026 BST			5-day change	1st Jan Change
26.42 ^HKD	+5.68%		+33.10%	-19.45%

1 day	+5.68%
1 week	+33.10%
Current month	+32.23%
1 month	+27.76%
3 months	+6.62%
6 months	-21.42%
Current year	-19.45%

1 week	18.9	26.96
1 month	18.88	26.96
Current year	18.88	43.3
1 year	18.88	52.9
3 years	18.88	69.15
5 years	18.88	69.15
10 years	18.88	69.15

	2026 *	2027 *
Net sales	67.73M 78.27M 9.98M 8.72M 8.02M 7.47M 14.17M 950M 14.39M 96.25M 37.42M 467M 37.46M 36.65M 1.61B	447M 517M 65.91M 57.62M 52.95M 49.36M 93.62M 6.28B 95.04M 636M 247M 3.08B 247M 242M 10.63B
Net income	-99M -114M -14.59M -12.75M -11.72M -10.92M -20.72M -1.39B -21.03M -141M -54.69M -683M -54.75M -53.57M -2.35B	-58M -67.02M -8.54M -7.47M -6.86M -6.4M -12.14M -814M -12.32M -82.41M -32.04M -400M -32.07M -31.39M -1.38B
Net Debt	-262M -303M -38.65M -33.78M -31.05M -28.94M -54.89M -3.68B -55.72M -373M -145M -1.81B -145M -142M -6.23B	486K 562K 71.61K 62.6K 57.53K 53.63K 102K 6.82M 103K 691K 268K 3.35M 269K 263K 11.55M

VISEN Pharmaceuticals Share Price

Stocks

2561

KYG93Y5D1039

Biotechnology & Medical Research

Valuation: VISEN Pharmaceuticals

Chart: VISEN Pharmaceuticals

Latest news : VISEN Pharmaceuticals

Quotes and Performance

Course Extremes

Managers and Directors: VISEN Pharmaceuticals

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise